An open-label, Phase I study of cediranib (RECENTIN™) in patients with acute myeloid leukemia

VEGFR and c-Kit signaling pathways may contribute to the pathophysiology of acute myeloid leukemia (AML). Thirty-five patients with AML received cediranib (RECENTIN (TM)), an oral, highly potent VEGF signaling inhibitor with c-Kit activity, at doses of <= 30 mg/day. The most common adverse events were diarrhea, hypertension and fatigue. Six patients experienced an objective response (3 each at 20 and 30 mg). Dose- and time-dependent reductions in sVEGFR-2 were observed, and there was a positive correlation between cediranib exposure and the change in plasma VEGF levels from baseline. Cediranib was generally well tolerated and showed preliminary evidence of activity as a monotherapy. (C) 2009 Elsevier Ltd. All rights reserved.